Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBLIVAC FIX Mite Mixture in House Dust Mite Allergy
NCT02345278Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- May 2015
- Primary completion
- Nov 2015
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of house dust mite allergen extract in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (5 arms), sponsored by HAL Allergy Group. Primary endpoint: Safety and tolerability of SUBLIVAC FIX Mite mixture at 1 month. Started May 2015; status: completed.
02
Drugs
house dust mite allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02345278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345278.